OncoSec signs on Dana-Farber as CAR-T partner; Dova racks up another Doptelet approval
→ Dana-Farber is lending a hand to little OncoSec’s nascent effort to develop CAR-T therapies for solid tumor cancers. The San Diego biotech has worked out an exclusive licensing deal with Wayne Marasco — an expert in antibody engineering — to apply his method of linking two single-chain variable fragment (scFv) in a bispecific CAR-T such that the T cells are only activated when both targets are engaged, thereby limiting off-tumor toxicity. OncoSec’s financial contribution in the research, which involves testing the experimental treatment solo and in combination with Tavo in triple-negative breast cancer, will be “modest” and spread over several years, CEO Daniel O’Connor said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.